secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dogwood Therapeutics, Inc. (DWTX)
CIK:        0001818844
Form:       8-K
Filed at:   2023-08-09T23:59:59+00:00
Accession:  0001558370-23-014077
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA deems IMC-1 chronic toxicology program adequate; Virios plans Phase 3 start mid-2024
--------------------------------------------------------------------------------

- FDA communicated that IMC-1 chronic toxicology studies appear adequate to support safety at proposed dose for chronic use.
- Virios plans to initiate a pharmacokinetic (pK) study this year and resubmit final Phase 3 program outline and protocols to FDA.
- Goal to begin enrollment in first fibromyalgia Phase 3 safety and efficacy study in mid-2024.
- Phase 3 plan includes two adequate and well-controlled studies and a long-term extension trial targeting community-based FM patients.
- Company to use 505(b)(2) regulatory pathway; FORTRESS Phase 2b results informed Phase 3 design.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1818844/000155837023014077/0001558370-23-014077-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1818844/000155837023014077/tmb-20230809x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-014077

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer